Compare LGL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGL | COCH |
|---|---|---|
| Founded | 1917 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 51.0M |
| IPO Year | 2017 | 2021 |
| Metric | LGL | COCH |
|---|---|---|
| Price | $6.78 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 12.5K | ★ 64.4K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 17.45 |
| EPS | N/A | N/A |
| Revenue | ★ $4,169,000.00 | $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $5.45 | $0.36 |
| 52 Week High | $7.88 | $1.89 |
| Indicator | LGL | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 49.85 |
| Support Level | $6.65 | $0.63 |
| Resistance Level | $7.35 | $0.73 |
| Average True Range (ATR) | 0.28 | 0.03 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 3.57 | 42.73 |
LGL Group Inc is a holding company engaged in services, merchant investment, and manufacturing business activities. The company has two reportable segments: Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications, including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.